Literature DB >> 10423257

Components of the bovine pituitary multicatalytic proteinase complex (proteasome) cleaving bonds after hydrophobic residues.

C Cardozo1, C Michaud, M Orlowski.   

Abstract

Two catalytic components of the multicatalytic proteinase complex (MPC, proteasome) designated as chymotrypsin-like (ChT-L) and branched chain amino acid preferring (BrAAP) cleave bonds after hydrophobic amino acids. The possible involvement of the ChT-L and peptidylglutamyl-peptide hydrolyzing (PGPH) activities in the cleavage of bonds attributed to the BrAAP component was examined. Several inhibitors of the ChT-L activity containing a phenylalaninal group did not affect the BrAAP activity at concentrations that were more than 150 times higher than their K(i) values for the ChT-L activity. Concentrations of lactacystin that inactivated more than 90% of the ChT-L activity had no effect on the BrAAP activity. Concentrations of 3,4-dichloroisocoumarin (DCI) that inactivated the ChT-L activity activated by up to 10-fold the BrAAP activity toward synthetic substrates and by more than 2-fold the degradation of the insulin B chain in a reaction not inhibited by Z-LGF-CHO, a selective inhibitor of the ChT-L activity. These findings are incompatible with any significant involvement of the ChT-L activity in the cleavage of BrAAP substrates. Both the native and DCI-treated MPC cleaved the insulin B chain mainly after acidic residues in a reaction inhibited by Z-GPFL-CHO, an inhibitor of the BrAAP and PGPH activities. DCI exposure did not result in acylation of the N-terminal threonine in the active site of the Y subunit. These results suggest involvement of the PGPH activity in the cleavage of BrAAP substrates, but this conclusion is incompatible with DCI activation of the BrAAP activity and inactivation of the PGPH activity, and with the finding that proteins inhibiting the PGPH activity had no effect on the BrAAP activity. Rationalization of these contradictions is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10423257     DOI: 10.1021/bi990735k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

Review 1.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

2.  Two-substrate association with the 20S proteasome at single-molecule level.

Authors:  Silke Hutschenreiter; Ali Tinazli; Kirstin Model; Robert Tampé
Journal:  EMBO J       Date:  2004-06-03       Impact factor: 11.598

Review 3.  The immunoproteasome as a target in hematologic malignancies.

Authors:  Deborah J Kuhn; Robert Z Orlowski
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

4.  A mathematical model of protein degradation by the proteasome.

Authors:  Fabio Luciani; Can Keşmir; Michele Mishto; Michal Or-Guil; Rob J de Boer
Journal:  Biophys J       Date:  2005-01-21       Impact factor: 4.033

5.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors:  Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.